Patients with secondary progressive MS on disease-modifying treatments often are clinically misclassified as having relapsing-remitting MS, most likely because they are not reassigned categorically until after conversion has occurred.
Ozone levels and DRB1 alleles represent independent factors that correlate with risk for pediatric MS, according to findings presented at MSVirtual2020.
In this video from MSVirtual2020, Jeffrey Cohen, MD, professor of medicine (neurology) at Cleveland Clinic Lerner College of Medicine and ACTRIMS president, provides an overview of what to expect from the meeting. The 8th Joint ACTRIMS-ECTRIMS Meeting is being held from Sept. 11-13, 2020, in a virtual format because of the COVID-19 pandemic.
